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Summary Immunohistological detection of P-glycoprotein (P-gp) with monoclonal antibody C219 was per- formed on serial sections of 37 neuroblastoma specimens representative of the different forms of the disease, from stage 1 ganglioneuroma to stage 4 neuroblastoma. Malignant cells, irrespective of their degree of
maturation varying from neuroblasts to ganglion cells, were negative on all specimens. The expression of
P-glycoprotein was detected in nine specimens, but it was restricted to normal cells within the tumour. In four
specimens, C219 reacted with normal infiltrating cells in the stroma (i.e. monocytes, histiocytes or fibroblasts) representing 5 to 10% of the total population within the section; in three specimens, the residual adrenal gland
was strongly positive, and in two ganglioneuromas, a weak reactivity of C219 was observed on a few satellite
cells and schwann cells. Three of 15 biopsies obtained at diagnosis contained normal P-gp positive cells: two
were classified as stage 1 ganglioneuromas; one was a typical stage 4 composite tumours with positive histiocytes and fibroblasts in the well-differentiated counterpart. Six of 22 biopsies obtained after patients had
received our current protocol of chemotherapy contained normal P-gp positive cells: five were partially differentiated and necrotic under the effect of chemotherapy; only one positive specimen was classified as undifferentiated neuroblastoma. Among negative specimens from previously treated patients, one was obtained from a patient in relapse after high-dose chemotherapy and ABMT, two were obtained from patients who had not responded to induction therapy, and six from patients in partial remission after induction therapy. The clinical evolution was very similar in both groups of patients with P-gp negative or positive biopsies. These findings suggest that the quantitative assessment of MDR RNA by northern blotting on fresh homogenates is likely to overestimate its expression on neuroblastoma cells, and that the mechanism of chemoresistance in widespread neuroblastoma is less likely to be associated with P-gp expression.
The relationship between the overexpression of the 170 kD
cell membrane glycoprotein (P-glycoprotein) and the pheno-
menon of multidrug resistance (MDR) has been clearly dem-
onstrated in human tumour cell lines; P-glycoprotein (P-gp)
functions as a drug-efflux pump which can be reversed in
vitro by calcium channel blockers such as Verapamil (Gerlach
et al., 1986; Rothenberg & Ling, 1989). The overexpression
of P-gp has been well documented in a number of tissues,
including liver, colon, kidney and adrenal gland, in untreated
human malignancies arising from these tissues, as well as in a
variety of tumours after treatment (Bell et al., 1985; Gerlach
et al., 1987; Ma et al., 1987; Epstein et al., 1989; Lai et al.,
1989; Merkel et al., 1989; Thiebaut et al., 1989; Cordon-
Cardo et al., 1990; Weinstein et al., 1990; Miller et al., 1991).
However, a meaningful relationship between the overexpres-
sion of P-gp and the resistance of these tumours to chemo-
therapy in vivo is not yet clear. Controversial conclusions
have been reported on the incidence of P-gp mRNA expres-
sion in neuroblastoma and its ability to predict the resistance
of widespread disease to chemotherapy (Goldstein et al.,
1990; Bourhis et al., 1989; Nakagawara et al., 1990). Dis-
crepancies may easily be accounted for by the use of molec-
ular techniques on bulk tissue in which the tumour cell
fraction is usually unknown; neuroblatoma specimens are
highly heterogeneous and often contaminated with residual
adrenal gland or kidney which express high levels of P-gp
mRNA. Conversely, immunohistochemistry can provide a
direct morphological confirmation of the presence of P-gp in
individual cells within the tumour (Schlaifer et al., 1990).
Monoclonal antibodies directed against different P-gp epi-
topes have been developed; a few variations in their reactivity
have been described in normal tissues, but a good concor-
dance is usually observed on malignant specimens (Thiebaut
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et al., 1989; Cordon-Cardo et al., 1990; Schlaifer et al., 1990;
Dalton et al., 1989; Sugawara et al., 1989; Broxterman et al.,
1989). C219 monoclonal antibody is directed to a well-con-
served cytoplasmic domain of the P-gp and its staining inten-
sity correlates directly to the degree of resistance to drug
influx in the cells (Kartner et al., 1985). This monoclonal
antibody has been used, in parallel with two others, on a
series of 182 human solid tumours; a strong expression of the
protein was evidenced with the three monoclonal antibodies
in 53 tumours, but seven neuroblastoma specimens were
negative (Cordon-Cardo et al., 1990).
In this report we describe the reactivity of C219 on serial
section of 37 neuroblastoma biopsies representative of the
different forms of the disease, from stage I ganglioneuroma
to stage 4 undifferentiated neuroblastoma. The P-gp expres-
sion was detected in nine specimens, but the positivity was
restricted to five to 10% normal infiltrating cells in the
stroma or to residual adrenal gland, whereas malignant cells
were negative.
Materials and methods
Patients and collection ofthe samples
Thirty-seven primary tumour samples were obtained from
institutes of the LMCE (Lyon-Marseille-Curie-East of
France) neuroblastomas study group in France. Biopsies of
the primary tumour were usually obtained at diagnosis for
low stage disease, or after the patient had received induction
therapy in advanced neuroblastoma; in Europe, primary
surgery in advanced neuroblastoma is usually delayed
because of surgical risk; it is thus ethically difficult to obtain
primary tumour biopsies at diagnosis. Patients' characteris-
tics are described in the two tables summarising the results.
Surgically obtained tumour samples were divided into three
parts, judged to be representative of the same lesion by
immediate examination of a frozen section; one part was
reserved for routine paraffin-embedded haematoxylin-eosin-
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stained histological analysis, one was kept for molecular
analysis, and the third one was frozen in isopentane and used
in this study for immunohistological analysis of P-gp expres-
sion. Tumours were histologically classified as typical neuro-
blastoma when they were fully undifferentiated with a poor
stroma, as ganglioneuroblastoma when they were partially
differentiated with a rich stroma, and as ganglioneuroma
when they were well differentiated.
Alkaline phosphatase immunostaining
P-gp was recognised by C219 mouse monoclonal antibody
(Centocor-Europ). Results were confirmed in four selected
specimens with MRK16 mouse monoclonal antibody (Hamada
& Tsuruo, 1986). Immunochemical staining was performed
using an indirect three-step immunoenzymatic procedure with
alkaline phosphatase (Dakopatts, Copenhagen, Denmark), as
already described (Combaret et al., 1989a). Briefly, air-dried
slides were fixed for 5 min with acetone at 4°C, incubated for
60 min with MoAbs, then for 30 min with enzyme-conjugated
rabbit anti-mouse immunoglobulins (Dakopatts) and for
30 min with enzyme-conjugated swine anti-rabbit immuno-
globulins (Dakopatts). Washes were performed using Tris
buffer. The final step consisted of a 15 min incubation with
Naphtol-As-Mx phosphate, dimethylformamide, levamisole
and fast red (Sigma Co., St Louis, USA). Slides were
counterstained with haematoxylin, mounted permanently
with glycerin and evaluated under optical microscope.
Immunohistological analysis was performed on serial sec-
tions. A minimum of two sections were analysed with C219
monoclonal antibody. Three sections were analysed in
parallel: one for staining and quantification of monocytes
and lymphocytes using anti-CD45 (Dakopatts, Denmark),
one for staining and quantification of neuroblastoma cells
using UJ I3A (kindly provided by Dr J. Kemshead) (Kems-
head et al., 1983), and one for histological controls. Further-
more, immunostaining with UJi 3A and anti-CD45 enabled
us to control the quality of samples (tissue preservation and
fixation). Expression was judged to be positive by com-
parison with three controls: VAC 75 drug-resistant cell line
used as positive control, normal peripheral lymphocytes used
as negative control, and one slide stained with irrelevant
monoclonal antibody.
To allow a more precise morphologic identification of the
neoplastic and non-neoplastic cell populations, four positive
biopsies were processed according to the ModAMeX method
recently described in detail by Delsol et al. (1989). Briefly,
tissues for the ModAMEX method were sliced approximately
2-3mm thick for 10min fixation at 4°C in cold acetone
containing protease inhibitors. Fragments were then sliced
into 1.5 mm thick fragments and left at -20°C to fix over-
night. Tissues were then dehydrated in aceton containing
protease inhibitors at 4°C for 15 min, and immersed in ace-
tone at room temperature for 15 min. Sections were cleared
in methyl benzoate for 15 min and subsequently in xylene for
15 min. Embedding was performed in a low melting point
paraplast (X-Tra, Carlo Erba). The ModAMex preparations
were warmed to 54°C for 2 min before deparaffinisation in
xylene for 10 min. Sections were then immersed in acetone
for 4 min, in Tris-buffered saline (TBS) plus acetone for
2 min, then in TBS for 4 min, and finally in TBS with bovine
serum albumin (1%) for 4 min. ModAMeX sections were
then stained as cryostat sections.
DNA analysis
N-myc amplification was quantified by southern-blot techni-
que, as previously described (Combaret et al., 1989b). After
extraction, 10ytg DNA from each sample were digested with
restriction enzyme EcoRl and separated by agarose gel elec-
trophoresis (1%). DNA fragments were denatured and trans-
ferred to a nylon membrane (Gene Screen plus, DuPont).
Hybridisation was performed with the N-myc probe pNb-I
(kindly provided by J. Minna, NCI), 32P-labelled by Amer-
sham 'Multi Primer Labelling System' to a specific activity of
about I0O c.p.m. ig-'. Restriction enzyme-digested tumour
DNAs were compared with lymphocyte DNA in the same
agarose gels and with the known N-myc amplified DNA of a
neuroblastoma cell line (SKNBE). The number of amplified
gene copies was measured by serial dilution of DNA to
obtain a hybridisation signal of two copy intensity (e.g. a
100-fold amplification is indicated when a 1:100 dilution
achieves two-copy intensity).
Results
Immunohistological detection of P-gp recognised by C219
was performed on 37 neuroblastoma specimens representative
of the different forms of the disease, from localised gang-
lioneuroma to metastatic neuroblastoma. Malignant cells,
irrespective of their degree of maturation, from neuroblasts
to ganglion cells, were negative in the 37 specimens. A
positive immunostaining was detected on nine specimens but
P-gp expression was restricted to normal cells. Eight of these
nine positive specimens were classified histologically as gang-
lionneuroblastomas or ganglioneuromas, whereas only one
was classified as undifferentiated neuroblastoma.
The negativity of malignant cells and the positivity of
normal cells were confirmed on four selected specimens (no
1, 15, 22 and 26) with monoclonal antibody MRK16. Fifteen
biopsies from patients with stage 1 to 4 or 4S disease were
obtained at diagnosis (Table I): three contained normal P-gp
positive cells. In two specimens classified as stage I gang-
lioneuromas (patients no 1 and 3; photographs I and J), 5%
of schwann cells and satellite cells weakly reacted with C219.
The third specimen was a typical composite stage 4 neuro-
blastoma: the immature counterpart of the tumour was nega-
tive but, in the well-differentiated counterpart, 5 to 10%
monocytes, histiocytes and fibroblasts expressed P-gp (patient
no 15; photographs C and D for C219 reactivity, and E for
MRK16 activity).
Twenty-two biopsies were obtained from patients with
stage 3, 4 or 4S disease after they had received our current
protocol of chemotherapy (Table II). In most samples,
chemotherapy had induced a partial differentiation of the
tumour and infiltration by monocytes and histiocytes in the
necrotic area. Six specimens contained normal P-gp positive
cells; in three of them (no 22, no 26 and no 32), 5 to 10%
infiltrating monocytes, histiocytes, and fibroblasts expressed
P-gp (photographs F, G and H); in the other three cases, a
strong positivity was observed on residual adrenal gland (no
23, 24 and 35; photographs K, and L). Sixteen of this series
of 22 specimens obtained from pre-treated patients were
negative, including specimens obtained from two patients
who had not responded to induction therapy, from six
patients in partial remission after induction therapy, as well
as biopsies obtained from one patient in relapse after
megatherapy and ABMT (see column 'clinical status at time
of biopsy' in Table II).
The presence of normal P-gp positive cells within the
samples did not predict either response to subsequent courses
of chemotherapy or clinical evoluation. Two of the nine
positive biopsies were obtained from patients (no 1 and no 3)
with stage 1-2 disease, who are well and free of disease
without any chemotherapy. The other seven were obtained
from patients with stage 4 disease: two patients, who received
no consolidation with megatherapy because they were under
1 year old (no 15 and no 35), are in complete remission after
induction therapy (10 months, 11 months + ); one patient (no
24) is in complete remission (36 months +) after mega-
therapy; four patients (no 22, no 23, no 26, no 32) relapsed
after megatherapy. This pattern of evolution is usual in
children suffering from neuroblatoma. Finally, southern-blot
analysis of the N-myc oncogene was performed in 30 of the
37 specimens; N-myc amplification was present in six speci-
mens, including two P-gp positive biopsies. N-myc amplifi-
cation was restricted to stage 3 and 4 neuroblastoma samples
and its presence in P-gp positive and negative specimens
reflected the usual incidence of this molecular defect in
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Table I Immunohistochemical detection of the P glycoprotein on 15 clinical neuroblastoma specimens at diagnosis
No PTT Stagea at P glycoprotein
(age in months) diagnosis Localiationb Histology expression N-myc Clinical evoluationc
1 (16) 1 Abdomen Ganglio-N + - CR (I month +)
2 (44) 1 Abdomen Ganglio-N - CR (22 months +)
3 (130) 1 Mediastinum Ganglio-N + - CR (6 months + )
4 (119) 1 Mediastinum Ganglio-N - - CR (I9 months + )
5 (40) 1 Mediastinum Ganglio-N - - CR (18 months + )
6 (14 years) 2 Mediastinum Ganglio-N - - CR (6 months + )
7 (9) 2 Mediastinum Ganglio-NB - - CR (26 months+ )
8 (45) 2 Mediastinum Ganglio-NB - - NE (I month +)
9 (26) 2 Abdomen Ganglio-NB - - CR (2 months+ )
10 (84) 3 Mediastinum Ganglio-NB - - CR (36 months + )
11 (10) 4S Mediastinum Ganglio-NB - - CR (24 months +)
12 (11) 4S Lympho node metas. NB - - CR (22 months +)
of primary mediastinal
tumour
13 (9) 4S Abdomen NB - - CR (17 months +)
14 (36) 4 Lymph node metas. NB - NT Relapse (I month
Of primary abdominal post graft)
tumour
15 (7) 4 Mediastinum Composite tumour + + CR (10 months +)
aPatients wereclassified according to theinternational classification (Brodeuretal., 1988).bP_glycoprotein wasanalysedon theprimary
tumour, otherwise specified. cCR: complete remission; PR: partial remission; NR: non responder; NE: non evaluable. All patients had
been treated with our current LMCE protocols (Philip & Pinkerton, 1989). Stages I and 2 patients did not receive chemoradiotherapy;
stage 3 and 4S patients had 6 month conventional chemotherapy. All stage 4 patients in this study, but no 15, no 35 and no 36, had
induction therapy and surgery, followed bymegatherapy, total bodyirradiation andautologous bonemarrow transplantation (ABMT).
Patients no 15 and no 35 (Table II) did not receive megatherapy because they were less than 12 months old; patient no 36 progressed
beforeentering the ABMTprogram. Clinical status at time ofbiopsy inTable II and subsequentclinical evolution in Table I and II were
evaluable according to our published rules (Philip et al., 1987).
Table II Immunohistological detection of the P glycoprotein on 22 clinical neuroblastoma specimens observed after induction therapy or from
patients in relapse
Clinical status Clinical evoluationc
No PTT Stagea at P glycoprotein at timec of (months post
(age/months) diagnosis Localiation b Histology expression N-myc biopsies diagnosis)
16 (23) 3 Abdomen Ganglio-NB - - CR CR (23 months + )
17 (27) 3 Abdomen Ganglio-NB - + CR Toxic death
18 (10) 3 Abdomen Ganglio-NB - NT CR CR (14 months + )
19 (3) 4S Abdomen NB - - CR CR (9 months +)
20 (6) 4S Abdomen NB - - CR CR (5 months+)
21 (18) 4 Mediastinum Ganglio-NB - - CR CR (29 months +)
22 (36) 4 Lymph node Ganglio-NB + NT PR Relapse
metastasis of
primary tumour
23 (27) 4 Abdomen Ganglio-NB + + CR Died in relapse
24 (26) 4 Abdomen Ganglio-NB + NT PR CR (36 months +)
25 (47) 4 Abdomen Ganglio-NB - - PR Toxic death
26 (42) 4 Abdomen Ganglio-NB + NT PR Died in relapse
27 (24) 4 Abdomen Ganglio-NB - NT PR NE
28 (29) 4 Abdomen Ganglio-NB - + PR Died in relapse
29 (17) 4 Abdomen Ganglio-NB - + CR Died in relapse
30 (48) 4 Abdomen Ganglio-NB - - PR Relapse (10 months)
31 (22 yrs) 4 Abdomen Ganglio-NB - - PR NE (I month +)
32 (123) 4 Abdomen NB + - PR Died in relapse
33 (48) 4 Abdomen Ganglio-NB - - NR Died in relapse
34 (54) 4 Mediatinum Ganglio-NB - - PR Alive in relapse
(22 months')
35 (3) 4 Abdomen Ganglio-NB + - PR CR (II months +)
36 (24) 4 Abdomen NB - + NR Progression
37 (37) 4 Abdomen Ganglio-NB - NT Relapse Died in relapse
aObxc See footnote to Table I. When patients are classified as CR at time of biopsy, the surgical excision of the tumour has been total.
Discussion
The immunohistological characterisation of P-gp expressing
cells with C219 in 37 neuroblastoma specimens representing
untreated primary diseases and chemosensitive or refractory
diseases enabled us to demonstrate that malignant cells at
any stage ofdifferentiation, from undifferentiated neuroblasts
to well-differentiated ganglion cells, were negative. A weak
positivity of schwann cells and satellite cells with C219 was
observed in only two cases of benign ganglioneuroma. In
seven other specimens, including six well-differentiated speci-
mens, P-gp expression was restricted to monocytes, histio-
cytes and fibroblasts in the stroma, or to residual adrenal
gland. The positivity of normal cells, observed both on low-
grade and widespread disease, did not correlate with response
or resistance to chemotherapy. These results, compared to
those of the literature, confirm the reliability of immunohis-
tochemical methods for studying P-gp expression in human
cancer. The reactivity of monoclonal antibodies directed
against different P-gp epitopes on the adrenal gland or on
stromal cells in human tumours has previously been reported
(Thiebaut el al., 1989; Schlaifer et al., 1990); in particular, in
non-hematopoietic tumours, Hodgkin and non-Hodgkin lym-
phomas, Schlaifer et al. (1990) have described the reactivity
of normal fibroblasts, monocytes, histiocytes and endothelial
cells with C219 and MRK16. In this study, we systematically236 M FAVROT et al.
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Figure 1 Immunoreactivity of normal cells with C219 on sections of neuroblastoma tumours. a, b, c, d and e: sections ( x 128)
from typical stage 4 composite tumour analysed at diagnosis (ppt no 15): Analysis of the P-gp expression was performed in serial
sections with two control slides: one of the staining of neuroblastoma with UJ13A a, the other one for the staining of lymphocytes,
monocytes or histiocytes with CD45 b; these two immunostainings also permitted to control the quality of preservation and
fixation. P-gp positive cells were stained with C219 (c and d) and MRK16 (e): in the mature counterparts, fibroblasts and clumps of
histiocytes are positive; the immature counterpart is negative (the tumour has been processed with the ModAMeX method to allow
a more precise identification of neoplastic and non-neoplastic cells). f: section ( x 128) from stage 4 neuroblastoma analysed after
the patients had received chemotherapy (ppt no 32): rare infiltrating histiocytes and lymphocytes strongly reacted with C219. g and
h: section ( x 128) from stage 4 ganglioneuroblastoma analysed after the patient had received chemotherapy (ptt no 26): large size
malignant cells are negative; within the population of small lymphocytes and histiocytes, 10 to 20% are positive with C219 (this
tumour has been processed with the ModAMeX method). i and j: sections ( x 128) from typical stage 1 ganglioneuroma (ptt no 1
and no 3): Satellite cells are positive (see arrows) but ganglion cells are negative on i: Schwann cells are positive (see arrows) on j.
k: section ( x 50) and 1: section ( x 80) from stage 4 ganglioneuroblastoma (ppt no 35): the positivity is restricted to residual
adrenal gland.
tested C219 reactivity on neuroblastoma, but the positivity of
monocytes, histiocytes and schwann cells, and the negativity
of malignant cells could be confirmed with MRK16 on four
selected specimens. Although C219 may cross-react with
ATP-binding sites in a few proteins (Weinstein et al., 1990),
its reactivity on adrenal gland and normal stromal cells
within neuroblastoma specimens is thus very likely to be P-gp
specific.
The negativity of malignant cells in all specimens, from
neuroblastoma to ganglioneuroma, questions the role of P-gp
in the resistance of widespread neuroblastoma to chemo-
therapy. In agreement with our results, Cordon-Cardo et al.
(1990) found no reactivity of seven neuroblastoma specimens
with C219, HYB-241 and HYB-612, whereas 53 of the other
175 tumours they analysed strongly reacted with those three
antibodies. However, in three other studies, a significant
expression of MDR1 mRNA was detected in neuroblastoma
specimens, though data and conclusions drawn by the
authors were controversial. Bourhis et al. (1989) detected
MDR1 mRNA in 12 of the 41 analysed specimens, and
Goldstein et al. (1990) in eight out of 49; both concluded to
its potential role in the chemoresistance of advanced neuro-
blastoma, based on the fact that the number of positive
specimens was higher in series analysed after the patient had
received chemotherapy than in series analysed at diagnosis.
Conversely, Nakagawara et al. (1990) detected MDR1
mRNA in well-differentiated low-stage disease rather than in
advanced stage 4 disease with N-myc amplification; the ana-
lysis of tumours obtained from patients with progressive
disease and/or in relapse were negative, and a sequential
study of tumours at diagnosis and after failure of chemo-
therapy did not demonstrate any increase in the MDR1
mRNA level.
The expression of P-gp on normal cells in neuroblastoma
specimens, as shown here, can help to explain these data.
First, the contamination of neuroblastoma specimens by
kidney or residual adrenal gland may well account for the
detection of MDR1 mRNA in some samples; MDR1 mRNA
measured in the adrenal gland is usually 10-fold higher than
levels observed in neuroblastoma specimens (Fojo et al.,
1987; Bourhis et al., 1989; Goldstein et al., 1990). The
presence of kidney or residual adrenal gland within surgical
specimens of neuroblastoma is not unusual in the case of
invasive tumours; in our series, residual adrenal gland was
still detectable in three specimens, although cryostat exam-
ination had been performed on all samples in order to
cryopreserve only the most representative counterpart of the
tumour. -Second, normal infiltrating cells expressing P-gp
were usually detected in the rich stroma of partially or
well-differentiated neuroblastoma; hence, the detection of P-
gp mRNA in well-differentiated specimens rather than in
undifferentiated neuroblastoma with a poor stroma in the
series of Nakagawara et al. (1990) is not surprising. Third,
chemotherapy is known to induce a partial differentiation of
stage 4 neuroblastoma, together with an histiocytic infil-
tration around the necrotic area; P-gp expression by normal
stromal cells, as observed in our study, may thus partially
account for a more frequent detection of MDR1 mRNA in
stage 4 tumours of previously treated patients than in those
of untreated patients (Goldstein et al., 1990; Bourhis et al.,
1989).
Other authors have made retrospective attempts to cor-
relate P-gp expression with clinical drug-resistance in various
tumours, but conclusions from the different studies are still
very controversial and further investigation is needed to
establish the clinical significance of this finding, its relation
with other biological features of the tumours and, eventually,
the potential use in clinics of the P-gp multidrug transfer
activity inhibition (Chabner & Wilson, 1991). The occurrence
of P-gp expression was until recently described in cell cul-
tures only; discrepancies between the results of multidrug
resistance analyses in tumoral specimens and in cell lines
derived from malignant tissues of similar histology have now
been well-documented in breast, ovarian or lung cancers
(Merkel et al., 1989; Ozols et al., 1987; Lai et al., 1989). An
overexpression of MDR1 mRNA by differentiating agents
had also been induced in vitro in a neuroblastoma cell line
(Bates et al., 1989), but our data understate the role of P-gp
in neuroblastoma chemoresistance in vivo.
In conclusion, the limitations of some laboratory tests used
to stratify patients into drug-sensitive and drug-resistant cate-
gories, such as the inability to discriminate between normal
and malignant cells when bulk tissues are analysed, must be
taken into consideration when correlating drug-resistance
and P-gp expression. The demonstration that P-gp expression
was restricted to normal cells within sections of neuroblast-
oma specimens requires reconsideration of its role in the
chemoresistance of this disease. In particular, the preferential
expression of MDR1 mRNA in tumours from previously
treated patients cannot be interpreted as the acquisition of
resistance to chemotherapy as long as direct morphologic
examination does not confirm the presence of P-gp in the
malignant cells. Although we cannot rule out that some
neuroblastoma cells may weakly express MDR1, this prob-
ably concerns very few tumoural specimens. Any further
attempt to evaluate the clinical relevance of P-gp expression
in neuroblastoma will require the analysis of both MDR1
mRNA and MDR protein at cell level; the development of in
situ hybridisation with nucleic adic probes on tissue sections
will help in the arrival at definitive conclusions.
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